scholarly journals Direct medical cost of complications in patients with Non Valvular Atrial Fibrillation NVAF at a Private Hospital in Venezuela

2015 ◽  
Vol 18 (3) ◽  
pp. A253
Author(s):  
Y. Fernandez ◽  
K. Chiquinquira ◽  
S. Garrido Lecca
Keyword(s):  
Atrial Fibrillation ◽  
Direct Medical Cost ◽  
Medical Cost ◽  
Private Hospital

scholarly journals Direct Medical Cost Of Complications In Patients With Non Valvular Atrial Fibrillation At The Social Security In Peru

2014 ◽  
Vol 17 (3) ◽  
pp. A132
Author(s):  
C Sanabria ◽  
J Cabrejos ◽  
C Guevara ◽  
A Olortegui ◽  
S Garrido Lecca
Keyword(s):  
Atrial Fibrillation ◽  
Social Security ◽  
Direct Medical Cost ◽  
Medical Cost ◽  
The Social

scholarly journals Health expenditure among the outpatient of type-2 diabetes in selected hospital of Kathmandu district: A cross-sectional study

2021 ◽  
Author(s):  
Rasmita shrestha ◽  
Aditya Shakya
Keyword(s):  
Direct Medical Cost ◽  
Direct Cost ◽  
Medical Cost ◽  
Public Hospital ◽  
Private Hospital ◽  
Total Direct Cost ◽  
Poor People ◽  
Diabetic Patients ◽  
Cross Sectional ◽  
Percentage Share

Introduction Pocket (OOP) expenditure is the dominant financing mechanism in low and middle-income countries. In these countries, the prevalence of diabetes has been rising more rapidly, leading to various microvascular complications, thus increasing the risk of dying prematurely. Methods A cross-sectional - comparative and hospital-based study was carried out in which OOP expenditure of diabetic patients treated in public and private hospitals was compared. A total of 154 diabetic patients i.e.77 in each type of hospital were selected purposively in consultation with attending physicians and staff. Face to face interview was done on a diabetic patient with a minimum of one year of illness using a structured questionnaire. Lorentz curve and concentration curve were prepared using the income and expenditure of the patients. Result Among 154 patients, 97.4% of patients had paid out of pocket for the treatment of diabetes. The mean direct cost per month was NRs. 7312.17 in public and NRs. 10125.31 in a private hospital. The direct medical cost had a higher share in total direct cost i.e. 60.5% in public and 69.3 % in a private hospital. Medicine cost had a higher percentage share (50.9%) in public hospital and laboratory cost had a higher percentage share (68%) in a private hospital. Conclusion The direct medical cost was higher in a private hospital as compared to a public hospital. All the income groups have to pay a similar amount of money for the treatment i.e. economic burden for the treatment of disease was found higher for the poor people as there was no financial protection mechanism.

scholarly journals PMS22 Direct Medical Cost of Osteoporosis in Saudi Arabia: A Single-Center Retrospective Cost Analysis

2020 ◽  
Vol 23 ◽  
pp. S596
Author(s):  
B. Balkhi ◽  
S. Alqusair ◽  
B. Alotaibi ◽  
A. Alghamdi ◽  
Y. AlRuthia ◽  
...  
Keyword(s):  
Saudi Arabia ◽  
Cost Analysis ◽  
Direct Medical Cost ◽  
Medical Cost ◽  
Single Center

scholarly journals EVALUATION OF PHARMACOECONOMIC DIRECT COST IN DIABETES PATIENTS

2017 ◽  
Vol 10 (4) ◽  
pp. 38
Author(s):  
Venkateswarlu Konuru ◽  
Kamala Sangam ◽  
Anifa Mohammed ◽  
Swathi Kanneganti
Keyword(s):  
Health Care ◽  
Diabetic Patient ◽  
Direct Medical Cost ◽  
Medical Cost ◽  
Average Cost ◽  
Health Care Cost ◽  
Vascular Complications ◽  
Illness Study ◽  
Total Average Cost ◽  
Total Average

Objective:  Diabetes Mellitus (DM) is a major cause of disability, morbidity and mortality Worldwide. The objective of this study is to evaluate the Pharmacoeconomic direct health care cost in type II Diabetes with complications and Diabetes alone: A cost of illness study. Methods:  A Prospective observational study was conducted for one year at the Care diabetes Center; Warangal. The enrolled patients were followed and the information collected contains: total direct costs, which include direct medical costs and direct nonmedical cost. The data observed was analyzed for the average cost incurred in treating the diabetic patient. Results:  The total average costs per diabetic patient without complications was Rs. 8695.7±1341,  this includes the average direct medical cost Rs. 6366.50± 561.12, the average lab cost Rs. 1368.84±64.8, the average direct non Medical Cost was Rs. 960.36±14.04 compared to  those with DM complications,the total average cost was Rs. 12960.73±549.96 for macro vascular complications, Rs. 11039.11±265.36 for micro vascular complications. To treat Diabetes with comorbidities which include both micro and macro complications the total average cost was  Rs. 16658.13±1393.44, the average direct medical cost was Rs. 14071.77±2884.68, the average lab cost Rs. 1628.04±51, the average direct non Medical Cost was Rs.958.32±13.08. The costs were found to increase progressively with the increase in the number of complications. Costs also differed significantly across the types of complications. Conclusion: Our study concludes that the cost of Diabetes with complications resulted about 2 times higher than compared to Diabetes alone.Key words:  Cost analysis; diabetes; economics; health care; direct medical cost; non medical cost

scholarly journals Direct medical cost of radiation therapy for cancer patients in Taiwan

Health ◽  
2013 ◽  
Vol 05 (06) ◽  
pp. 989-993
Author(s):  
Henry W. C. Leung ◽  
Agnes L. F. Chan
Keyword(s):  
Radiation Therapy ◽  
Direct Medical Cost ◽  
Cancer Patients ◽  
Medical Cost

scholarly journals Economic Burden of Tuberculosis Diabetes Co-Morbidity in Tuberculosis Patients Attending Two Chest Clinics in Lagos State

2021 ◽  
Vol 16 (2) ◽  
pp. 91-100
Author(s):  
F.A. Ayeni ◽  
O.O. Oyetunde ◽  
B.A. Aina ◽  
H.O. Yarah
Keyword(s):  
Direct Medical Cost ◽  
Medical Cost ◽  
Indirect Costs ◽  
Medical Costs ◽  
Female Patients ◽  
Direct Medical Costs ◽  
Tb Treatment ◽  
Co Morbidity ◽  
Lagos State ◽  
Significant Burden

Background: Diabetes mellitus (DM) increases the risk of developing tuberculosis (TB) three-fold. The cost of accessing care for TB-DM co-morbidity poses a significant burden on patients, as they bear both direct and indirect costs of treatment, mostly of out-of-pocket.Objective: To estimate the direct medical cost of illness in patients with TB-DM co-morbidity in two chest clinics in Lagos State.Materials and Methods: An observational study, carried out in two chest clinics in Lagos State to evaluate direct medical costs associated with TBDM co-morbidity during TB treatment. A semi structured questionnaire, pharmacy price list of drugs and an online transportation service lara.ng was employed to document and quantify prescribed medications, laboratory investigations, number of clinic attendance and attendant transportation costs.Results: Among the participants, 53.8% were females. The mean age was 50.7±9.7 years. The total direct medical and non-medical costs for TBDM management was NGN8,604,819 (USD24,585.20) for the duration of TB treatment. Average cost per patient (CPP) was NGN179,384.85 (USD512.53). This was equivalent to 49.8% of the current national minimum wage. Male patients incurred more mean direct medical cost than female patients (NGN26, 647.90 vs NGN24, 020.40), while female patients incurred more mean direct non-medical costs than the males (NGN22, 314.30 versus NGN13, 041.70). Patients aged 60 years and above incurred the highest mean direct costs compared to other age groups.Conclusion: Direct medical costs are substantial in TBDM co-morbidity and increase with age.

The health and economic burden of chickenpox and herpes zoster in Belgium

2012 ◽  
Vol 140 (11) ◽  
pp. 2096-2109 ◽  
Author(s):  
J. BILCKE ◽  
B. OGUNJIMI ◽  
C. MARAIS ◽  
F. DE SMET ◽  
M. CALLENS ◽  
...  
Keyword(s):  
Herpes Zoster ◽  
General Practitioner ◽  
Direct Medical Cost ◽  
Medical Cost ◽  
Quality Adjusted Life Years ◽  
Varicella Zoster ◽  
Hospitalization Rates ◽  
Life Years ◽  
Life Years Lost ◽  
Quality Adjusted Life

SUMMARYVaricella-zoster virus causes chickenpox (CP) and after reactivation herpes zoster (HZ). Vaccines are available against both diseases warranting an assessment of the pre-vaccination burden of disease. We collected data from relevant Belgian databases and performed five surveys of CP and HZ patients. The rates at which a general practitioner is visited at least once for CP and HZ are 346 and 378/100 000 person-years, respectively. The average CP and HZ hospitalization rates are 5·3 and 14·2/100 000 person-years respectively. The direct medical cost for HZ is about twice as large as the direct medical cost for CP. The quality-adjusted life years lost for ambulatory CP patients consulting a physician is more than double that of those not consulting a physician (0·010vs. 0·004). In conclusion, both diseases cause a substantial burden in Belgium.

Sign in / Sign up

Export Citation Format

Share Document